How to treat drug-resistant rare gynecological cancers? Immunotherapy Avelumab shows off
-
Last Update: 2020-06-05
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Pregnancy Nourishing Cell Tumor (GTT) is a very rare gynaecological cancer that occurs during or after pregnancyGTT is caused by abnormal growth of the endometrial during conceptionAvelumab is a checkpoint inhibitor that blocks PD-L1 on tumor cellsBecause GTT over-expresss PD-L1, Avelumab is a potential treatment for GTTa small Phase II study showed that Avenab has the potential to cure GTT, and the results will be revealed at the 2020 annual meeting of the American Society of Clinical Oncology (ASCO)In this study, 15 GTT patients who were resistant to methotrexate or lineme-D were treated with Bavencio, 8 of which (53%) showed no signs of recurrence during 29 months of follow-upIf the disease does not recur after 12 months and monitoring of human fluff membrane gonadotropin (hCG, GTT biomarker) has been completed, the researchers believe the patient has been curedDr Howard ABurris, chairman of ASCO, said: "Given the proportion of patients without relapse and good safety data, Avelumab deserves further study."
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
